PTC Therapeutics plans to request approval for its GT-AADC gene therapy, developed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, in the United States. Supported by positive data from clinical studies, the company expects to submit a biologics license application (BLA) with the U.S. Food and Drug Administration…
News
Recent Posts
- NORD adds 7 sites in 5 states as Rare Disease Centers of Excellence
- Simple strategies and new exercises help to correct mouth breathing
- New AI tool for doctors’ notes may save patients years to be diagnosed
- Computer-guided surgery delivers gene therapy to 2 children
- This Thanksgiving, I’m expressing gratitude and hope for the future